Evidence map›Paper›PMID 27119551›Full record

ArticleAmerican journal of respiratory and critical care medicine2016

HIPPO-Integrin-linked Kinase Cross-Talk Controls Self-Sustaining Proliferation and Survival in Pulmonary Hypertension.

Tatiana V Kudryashova, Dmitry A Goncharov, Andressa Pena, Neil Kelly, Rebecca Vanderpool, Jeff Baust, Ahasanul Kobir, William Shufesky, Ana L Mora, Adrian E Morelli and 10 more

Open access · greenAbstract read
In one paragraph

Article in American journal of respiratory and critical care medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 145 citations in OpenAlex.

  1. Review
  2. Mechanical compression causes lung hypoplasia in congenital diaphragmatic hernia with GATA4 genetic variants.American journal of physiology. Lung cellular and molecular physiology · 2026
    Article
  3. Review
  4. The emerging role of integrin signaling in pulmonary vascular disease.American journal of physiology. Lung cellular and molecular physiology · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Will Stub1 Be the Next Target for Pulmonary Hypertension Therapy Development?American journal of respiratory cell and molecular biology · 2025
    Article
  12. Article
  13. Signaling pathways and targeted therapy for pulmonary hypertension.Signal transduction and targeted therapy · 2025
    Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 3 countries.

Tatiana V Kudryashova1 Heart, Lung, Blood and Vascular Medicine Institute.ORCID http://orcid.org/0000-0002-2843-5554
Dmitry A Goncharov1 Heart, Lung, Blood and Vascular Medicine Institute.
Andressa Pena1 Heart, Lung, Blood and Vascular Medicine Institute.
Neil Kelly2 Department of Medicine, and.
Rebecca Vanderpool1 Heart, Lung, Blood and Vascular Medicine Institute.
Jeff Baust1 Heart, Lung, Blood and Vascular Medicine Institute.
Ahasanul Kobir1 Heart, Lung, Blood and Vascular Medicine Institute.
William Shufesky3 Department of Surgery and Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Ana L Mora1 Heart, Lung, Blood and Vascular Medicine Institute.
Adrian E Morelli3 Department of Surgery and Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Jing Zhao2 Department of Medicine, and.
Kaori Ihida-Stansbury4 Department of Pathology and Laboratory Medicine.
Baojun Chang1 Heart, Lung, Blood and Vascular Medicine Institute.
Horace DeLisser5 Pulmonary Vascular Disease Program.
Rubin M Tuder7 Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Denver, Aurora, Colorado; and.
Steven M Kawut5 Pulmonary Vascular Disease Program.
Herman H W Silljé9 Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Steven Shapiro2 Department of Medicine, and.
Yutong Zhao1 Heart, Lung, Blood and Vascular Medicine Institute.
Elena A Goncharova1 Heart, Lung, Blood and Vascular Medicine Institute.ORCID http://orcid.org/0000-0001-7118-6752
Pulmonary Vascular Research Institute · GBUniversity of Pittsburgh · USUniversity Medical Center Groningen · NLUniversity of Colorado Denver · US

Funding

Vascular Subphenotypes of Lung DiseaseP01HL103455 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SHIVA, SRUTI · 2011 to 2020
$26.1M
Pulmonary Hypertension Breakthrough InitiativeR24HL123767 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI ALDRED, MICHEALA A, ERZURUM, SERPIL C. · 2014 to 2017
$10.1M
Translational Pulmonary Vascular BiologyT32HL110849 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Sruti Shiva · 2012 to 2026
$5.0M
HIPPO Signaling in Pulmonary Arterial HypertensionR01HL130261 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GONCHAROVA, ELENA · 2016 to 2023
$3.5M
TSC2 Signaling in Pulmonary Arterial HypertensionR01HL113178 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GONCHAROVA, ELENA · 2012 to 2021
$3.1M
Mentored Patient-Oriented Research in Pulmonary Arterial HypertensionK24HL103844 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI KAWUT, STEVEN M · 2011 to 2020
$1.6M
Regulation of Histone Acetyltransferase Stability In SepsisR01GM115389 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ZHAO, JING · 2015 to 2019
$1.5M
NHLBI NIH HHS K24 HL103844NHLBI NIH HHS P01 HL103455NHLBI NIH HHS R01 HL113178NHLBI NIH HHS R01 HL130261NHLBI NIH HHS R24 HL123767NHLBI NIH HHS T32 HL110849NIGMS NIH HHS R01 GM115389
6 · The paper itself

Abstract

rationaleEnhanced proliferation and impaired apoptosis of pulmonary arterial vascular smooth muscle cells (PAVSMCs) are key pathophysiologic components of pulmonary vascular remodeling in pulmonary arterial hypertension (PAH).

objectivesTo determine the role and therapeutic relevance of HIPPO signaling in PAVSMC proliferation/apoptosis imbalance in PAH.

methodsPrimary distal PAVSMCs, lung tissue sections from unused donor (control) and idiopathic PAH lungs, and rat and mouse models of SU5416/hypoxia-induced pulmonary hypertension (PH) were used. Immunohistochemical, immunocytochemical, and immunoblot analyses and transfection, infection, DNA synthesis, apoptosis, migration, cell count, and protein activity assays were performed in this study. MEASUREMENTS AND MAIN

resultsImmunohistochemical and immunoblot analyses demonstrated that the HIPPO central component large tumor suppressor 1 (LATS1) is inactivated in small remodeled pulmonary arteries (PAs) and distal PAVSMCs in idiopathic PAH. Molecular- and pharmacology-based analyses revealed that LATS1 inactivation and consequent up-regulation of its reciprocal effector Yes-associated protein (Yap) were required for activation of mammalian target of rapamycin (mTOR)-Akt, accumulation of HIF1α, Notch3 intracellular domain and β-catenin, deficiency of proapoptotic Bim, increased proliferation, and survival of human PAH PAVSMCs. LATS1 inactivation and up-regulation of Yap increased production and secretion of fibronectin that up-regulated integrin-linked kinase 1 (ILK1). ILK1 supported LATS1 inactivation, and its inhibition reactivated LATS1, down-regulated Yap, suppressed proliferation, and promoted apoptosis in PAH, but not control PAVSMCs. PAVSM in small remodeled PAs from rats and mice with SU5416/hypoxia-induced PH showed down-regulation of LATS1 and overexpression of ILK1. Treatment of mice with selective ILK inhibitor Cpd22 at Days 22-35 of SU5416/hypoxia exposure restored LATS1 signaling and reduced established pulmonary vascular remodeling and PH.

conclusionsThese data report inactivation of HIPPO/LATS1, self-supported via Yap-fibronectin-ILK1 signaling loop, as a novel mechanism of self-sustaining proliferation and apoptosis resistance of PAVSMCs in PAH and suggest a new potential target for therapeutic intervention.

Indexed as

HIPPO/LATS1ILKPAHproliferation/apoptosis imbalancevascular smooth muscle

Identifiers

PMID27119551
PMCPMC5074651
OpenAlexW2344643399

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.